De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy (Supplemental Material)
Published: 14 May 2024| Version 1 | DOI: 10.17632/r9r5pj2fzy.1
Contributors:
Olivia Jew, Winston Liu, Christopher Stamey, Meenal Kheterpal, Sarah Myers, Matthew Ellis, Jennifer Byrns, Lee Wheless, Melodi WhitleyDescription
Supplemental data.
Files
Categories
Dermatology, Skin Cancer, Organ Transplantation, Immunosuppression